Athymic nude mice as an experimental model for cancer treatment

I Szadvari1, O Krizanova, P Babula

  • 1Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. babula@med.muni.cz.

Physiological Research
|December 24, 2016
PubMed

Insights

Athymic nude mice, lacking a thymus, are crucial for cancer research and preclinical drug testing. This review covers models, evaluation methods, and the strengths and weaknesses of this essential research tool.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Athymic nude mice possess a defective thymus due to a Foxn1 gene deletion, leading to an impaired immune system with reduced T cells.
  • These mice are a long-established and widely utilized model in cancer research for preclinical drug evaluation.

Purpose of the Study:

  • To review established athymic nude mouse models for tumor induction using cancer cell lines.
  • To discuss various methods for evaluating anticancer agent activity within these models.
  • To summarize the strengths, weaknesses, and future perspectives of athymic nude mice in cancer research.

Main Methods:

  • Description of three distinct athymic nude mouse models employing cancer cell lines for tumor xenografting.
  • Discussion of diverse methodologies for assessing the efficacy of anticancer agents in vivo.
  • Comprehensive review of existing literature on athymic nude mouse applications in cancer research.

Main Results:

  • Athymic nude mouse models, despite inherent limitations, remain indispensable for cancer research.
  • These models facilitate the preclinical testing of novel anticancer drugs and the enhancement of existing chemotherapies.
  • The review consolidates critical insights into the utility and application of these mice.

Conclusions:

  • Athymic nude mice are vital instruments in cancer research, particularly for drug discovery and development.
  • Understanding their strengths and weaknesses is crucial for optimizing their use in preclinical studies.
  • Future research should continue to leverage and refine these models for advancing cancer treatment strategies.